etoposide has been researched along with incb-018424 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 7 (63.64) | 2.80 |
| Authors | Studies |
|---|---|
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Sin, JH; Zangardi, ML | 1 |
| Jin, Z; Wang, J; Wang, Y; Wang, Z; Wu, L; Zhang, J | 1 |
| Fan, L; Li, JY; Miao, Y | 1 |
| Chen, C; Gao, Y; Guan, Z; Li, M; Liu, Y; Pan, X; Qiu, S; Wang, H; Wen, Z; Yang, S; Yuan, Y; Zeng, W; Zhang, H; Zhou, L; Zhu, Q | 1 |
| Jing, X; Tang, H; Wang, S; Wu, J; Zhang, Y | 1 |
| Guo, H; Li, F; Li, H; Liu, L; Mai, H; Wang, J; Wang, Z; Wu, X; Yang, H; Zhang, R; Zhang, X | 1 |
| Huang, Z; Xie, J | 1 |
| Xu, XJ; Yan, WL; Yang, SL; Zhao, FY | 1 |
| Noto, A; Obeid, M; Pantaleo, G; Segot, A; Spertini, O; Stalder, G; Suffiotti, M | 1 |
| Chen, C; Gan, YZ; Jia, Y; Jin, YB; Li, C; Li, GM | 1 |
2 review(s) available for etoposide and incb-018424
| Article | Year |
|---|---|
Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Phytogenic; Drug Therapy, Combination; Etoposide; Female; Humans; Janus Kinases; Lymphohistiocytosis, Hemophagocytic; Nitriles; Pregnancy; Pregnancy Complications; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Topoisomerase II Inhibitors | 2019 |
[Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].
Topics: Aged; Anti-Bacterial Agents; Dexamethasone; Epstein-Barr Virus Infections; Etoposide; Exanthema; Female; Ferritins; Fibrinogen; Glucocorticoids; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Panniculitis; Prednisone | 2022 |
2 trial(s) available for etoposide and incb-018424
| Article | Year |
|---|---|
Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubicin; Etoposide; Female; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methylprednisolone; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Salvage Therapy | 2021 |
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Topics: Adult; Clinical Trials as Topic; Dexamethasone; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Pilot Projects | 2023 |
7 other study(ies) available for etoposide and incb-018424
| Article | Year |
|---|---|
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
Topics: Anti-Inflammatory Agents; Biomarkers; Dexamethasone; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Janus Kinase 1; Janus Kinase 2; Lymphohistiocytosis, Hemophagocytic; Middle Aged; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus.
Topics: Child; Chronic Disease; DNA, Viral; Drug Resistance, Viral; Epstein-Barr Virus Infections; Etoposide; Fever; Ganciclovir; Herpesvirus 4, Human; Humans; Male; Methylprednisolone; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Splenomegaly; Viral Load; Viremia | 2019 |
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Etoposide; Humans; Immunomodulation; Interleukin-6; Lymphohistiocytosis, Hemophagocytic; Nitriles; Pandemics; Pneumonia, Viral; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Retrospective Studies | 2020 |
Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
Topics: Adolescent; Clinical Protocols; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Induction Chemotherapy; Intensive Care Units; Lymphohistiocytosis, Hemophagocytic; Methylprednisolone; Nitriles; Polyethylene Glycols; Pyrazoles; Pyrimidines; Treatment Outcome | 2021 |
Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Topics: Acute Kidney Injury; Child, Preschool; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Nitriles; Pyrazoles; Pyrimidines | 2022 |